We’ve issued final draft guidance recommending a new once-a-day tablet that is set to benefit around 1,100 people with a type ...

NICE is proposing changes to its routing criteria for Highly Specialised Technologies (HST) to ensure more consistent, ...

Anhydrous sodium thiosulfate, also known as Pedmarqsi and made by Norgine, is recommended in final draft guidance for preventing hearing loss caused by cisplatin chemotherapy in children from the ages ...

Tirzepatide is recommended as an option for managing overweight and obesity, alongside a reduced-calorie diet and increased physical activity in adults, only if they have: an initial body mass index ...

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...

A list of downloadable documents created during development.

If you’re commenting for an organisation, your organisation needs to be registered as a stakeholder. We can accept comments from individuals. These will be considered, but you won’t get a formal ...

Tirzepatide (Mounjaro, Eli Lilly) is a long-acting dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide‑1 (GLP‑1) receptor agonist for subcutaneous injection with a ...

NICE inherited the 7 highly specialised technologies (HST) routing criteria from AGNSS (Advisory Group for National Specialised Services) in 2013. Following that, the NICE Highly Specialised ...

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...